Physician profile
Jacquelyn Mclean Bennett
NPI 1639185416
$11,050.68
in general payments reported to CMS, 2019-2025
49 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $1,534 · 2021: $1,530 · 2022: $1,620 · 2023: $1,854 · 2024: $1,657 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,802.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,691.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,281.93 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,110.77 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $946.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $715.24 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $651.44 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $542.00 | 2019-2024 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $453.84 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.46 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $298.50 | 2019-2025 | Belsomra, Steglatro, M-M-R II |
| Otsuka America Pharmaceutical, INC. | $294.09 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $276.50 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $243.36 | 2021-2025 | |
| Astellas Pharma US INC | $239.35 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $215.63 | 2019-2024 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Mclean Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.